Several experimental biologic drugs that failed in the US and Europe have been recently approved in China.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: a meta-analysis
World Journal of Surgical Oncology Open Access 26 February 2021
-
“Right-to-Try” experimental drugs: an overview
Journal of Translational Medicine Open Access 23 June 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
China beckons to clinical trial sponsors
China approves first gene therapy
Can China bring its own pipeline to the market?
Web links
Rights and permissions
About this article
Cite this article
Jia, H., Kling, J. China offers alternative gateway for experimental drugs. Nat Biotechnol 24, 117–118 (2006). https://doi.org/10.1038/nbt0206-117
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0206-117
This article is cited by
-
Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: a meta-analysis
World Journal of Surgical Oncology (2021)
-
“Right-to-Try” experimental drugs: an overview
Journal of Translational Medicine (2020)
-
Expression of liver-targeting peptide modified recombinant human endostatin and preliminary study of its biological activities
Applied Microbiology and Biotechnology (2014)
-
Different combination schedules of gemcitabine with endostar affect antitumor efficacy
Cancer Chemotherapy and Pharmacology (2012)
-
Innovation capacity and economic development: China and India
Economic Change and Restructuring (2011)
